    6 ADVERSE REACTIONS

  The following adverse reactions are discussed in greater detail in other sections of the label:



 *   Hepatotoxicity≠B-OSE_Labeled_AE  [See  Warnings and Precautions (5.1)  ]  
 *   Left≠B-OSE_Labeled_AE   Ventricular≠I-OSE_Labeled_AE   Dysfunction≠I-OSE_Labeled_AE  [See  Warnings and Precautions (5.2)  ]  
 *   Embryo≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  Fetal≠I-OSE_Labeled_AE   Toxicity≠I-OSE_Labeled_AE  [See  Warnings and Precautions (5.3)  ]  
 *   Pulmonary≠B-OSE_Labeled_AE   Toxicity≠I-OSE_Labeled_AE  [See  Warnings and Precautions (5.4)  ]  
 *   Infusion≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  Related≠I-OSE_Labeled_AE   Reactions≠I-OSE_Labeled_AE ,  Hypersensitivity≠B-OSE_Labeled_AE   Reactions≠I-OSE_Labeled_AE  [See  Warnings and Precautions (5.5)  ]  
 *   Hemorrhage≠B-OSE_Labeled_AE  [See  Warnings and Precautions (5.6)  ]  
 *   Thrombocytopenia≠B-OSE_Labeled_AE  [See  Warnings and Precautions (5.7)  ]  
 *   Neurotoxicity≠B-OSE_Labeled_AE  [See  Warnings and Precautions (5.8)  ]  
      EXCERPT:   The most common adverse drug reactions (frequency > 25%) with KADCYLA (n=884 treated patients) were fatigue, nausea, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, increased transaminases, constipation and epistaxis. (  6.1  )
 

   To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  



 

  6.1 Clinical Trials Experience

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.



 In clinical trials, KADCYLA has been evaluated as single-agent in 884 patients with  HER≠B-Not_AE_Candidate  2≠I-Not_AE_Candidate  -≠I-Not_AE_Candidate  positive≠I-Not_AE_Candidate  metastatic  breast≠I-Not_AE_Candidate   cancer≠I-Not_AE_Candidate . The most common (frequency >= 25%) adverse drug reactions (ADRs) seen in 884 patients treated with KADCYLA were  fatigue≠B-OSE_Labeled_AE ,  nausea≠B-OSE_Labeled_AE ,  musculoskeletal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  hemorrhage≠B-OSE_Labeled_AE ,  thrombocytopenia≠B-OSE_Labeled_AE ,  headache≠B-OSE_Labeled_AE ,  increased≠B-OSE_Labeled_AE   transaminases≠I-OSE_Labeled_AE ,  constipation≠B-OSE_Labeled_AE  and  epistaxis≠B-OSE_Labeled_AE .



 The ADRs described in  Table 6  were identified in patients with  HER≠B-Not_AE_Candidate  2≠I-Not_AE_Candidate  -≠I-Not_AE_Candidate  positive≠I-Not_AE_Candidate  metastatic  breast≠I-Not_AE_Candidate   cancer≠I-Not_AE_Candidate  treated in a randomized trial (Study 1)  [see  Clinical Studies (14.1)  ]  . Patients were randomized to receive KADCYLA or lapatinib plus capecitabine. The median duration of study treatment was 7.6 months for patients in the KADCYLA-treated group and 5.5 months and 5.3 months for patients treated with lapatinib and capecitabine, respectively. Two hundred and eleven (43.1%) patients experienced >= Grade 3 adverse events in the KADCYLA-treated group compared with 289 (59.2%) patients in the lapatinib plus capecitabine-treated group. Dose adjustments for KADCYLA were permitted  [see  Dosage and Administration (2.2)  ]  . Thirty-two patients (6.5%) discontinued KADCYLA due to an adverse event, compared with 41 patients (8.4%) who discontinued lapatinib, and 51 patients (10.5%) who discontinued capecitabine due to an adverse event. The most common adverse events leading to KADCYLA withdrawal were  thrombocytopenia≠B-OSE_Labeled_AE  and  increased≠B-OSE_Labeled_AE   transaminases≠I-OSE_Labeled_AE . Eighty patients (16.3%) treated with KADCYLA had adverse events leading to dose reductions. The most frequent adverse events leading to dose reduction of KADCYLA (in >= 1% of patients) included  thrombocytopenia≠B-OSE_Labeled_AE ,  increased≠B-OSE_Labeled_AE   transaminases≠I-OSE_Labeled_AE , and  peripheral≠B-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE . Adverse events that led to dose delays occurred in 116 (23.7%) of KADCYLA treated patients. The most frequent adverse events leading to a dose delay of KADCYLA (in >= 1% of patients) were  neutropenia≠B-OSE_Labeled_AE ,  thrombocytopenia≠B-OSE_Labeled_AE ,  leukopenia≠B-OSE_Labeled_AE ,  fatigue≠B-OSE_Labeled_AE ,  increased≠B-OSE_Labeled_AE   transaminases≠I-OSE_Labeled_AE  and  pyrexia≠B-OSE_Labeled_AE .



   Table 6  reports the ADRs that occurred in patients in the KADCYLA-treated group (n=490) of the randomized trial (Study 1). Selected  laboratory≠B-NonOSE_AE   abnormalities≠I-NonOSE_AE  are shown in  Table 7  . The most common ADRs seen with KADCYLA in the randomized trial (frequency > 25%) were  nausea≠B-OSE_Labeled_AE ,  fatigue≠B-OSE_Labeled_AE ,  musculoskeletal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE ,  hemorrhage≠B-OSE_Labeled_AE ,  thrombocytopenia≠B-OSE_Labeled_AE ,  increased≠B-OSE_Labeled_AE   transaminases≠I-OSE_Labeled_AE ,  headache≠B-OSE_Labeled_AE , and  constipation≠B-OSE_Labeled_AE . The most common NCI-CTCAE (version 3) >= Grade 3 ADRs (frequency >2%) were  thrombocytopenia≠B-OSE_Labeled_AE ,  increased≠B-OSE_Labeled_AE   transaminases≠I-OSE_Labeled_AE ,  anemia≠B-OSE_Labeled_AE ,  hypokalemia≠B-OSE_Labeled_AE ,  peripheral≠B-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE  and  fatigue≠B-OSE_Labeled_AE .



 Table 6 Summary of Adverse Drug Reactions Occurring in Patients on the KADCYLA Treatment Arm in the Randomized Trial (Study 1) 
 Adverse Drug Reactions (MedDRA)System Organ Class  KADCYLA(3.6 mg/kg)n=490Frequency rate %  Lapatinib (1250 mg) + Capecitabine (2000 mg/m  2  )n=488Frequency rate %   
                                           All grades (%)   Grade 3 - 4 (%)  All grades (%)   Grade 3 - 4 (%)   
  
 ND = Not determined                        
  
    Blood≠B-NonOSE_AE   and≠I-NonOSE_AE   Lymphatic≠I-NonOSE_AE   System≠I-NonOSE_AE   Disorders≠I-NonOSE_AE      
  Neutropenia≠B-OSE_Labeled_AE                                      6.7              2.0              9.0              4.3         
  Anemia≠B-OSE_Labeled_AE                                          14.3              4.1             10.5              2.5         
  Thrombocytopenia≠B-OSE_Labeled_AE                                31.2             14.5              3.3              0.4         
    Cardiac≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                         
  Left≠B-OSE_Labeled_AE   ventricular≠I-OSE_Labeled_AE   dysfunction≠I-OSE_Labeled_AE                     1.8              0.2              3.3              0.4         
    Eye≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                             
  Lacrimation≠B-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE                            3.3               0               2.5               0          
  Dry≠B-OSE_Labeled_AE   eye≠I-OSE_Labeled_AE                                          3.9               0               3.1               0          
  Vision≠B-OSE_Labeled_AE   blurred≠I-OSE_Labeled_AE                                   4.5               0               0.8               0          
  Conjunctivitis≠B-OSE_Labeled_AE                                   3.9               0               2.3               0          
    Gastrointestinal≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                
  Dyspepsia≠B-OSE_Labeled_AE                                        9.2               0              11.5              0.4         
  Stomatitis≠B-OSE_Labeled_AE                                      14.1              0.2             32.6              2.5         
  Dry≠B-OSE_Labeled_AE   Mouth≠I-OSE_Labeled_AE                                       16.7               0               4.9              0.2         
  Abdominal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE                                  18.6              0.8             17.6              1.6         
  Vomiting≠B-OSE_Labeled_AE                                        19.2              0.8             29.9              4.5         
  Diarrhea≠B-OSE_Labeled_AE                                        24.1              1.6             79.7             20.7         
  Constipation≠B-OSE_Labeled_AE                                    26.5              0.4             11.1               0          
  Nausea≠B-OSE_Labeled_AE                                          39.8              0.8             45.1              2.5         
    General≠B-NonOSE_AE   Disorders≠I-NonOSE_AE   and≠I-NonOSE_AE   Administration≠I-NonOSE_AE      
  Peripheral≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE                                 7.1               0               8.2              0.2         
  Chills≠B-OSE_Labeled_AE                                           7.6               0               3.1               0          
  Pyrexia≠B-OSE_Labeled_AE                                         18.6              0.2              8.4              0.4         
  Asthenia≠B-OSE_Labeled_AE                                        17.8              0.4             17.6              1.6         
  Fatigue≠B-OSE_Labeled_AE                                         36.3              2.5             28.3              3.5         
    Hepatobiliary≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                   
  Nodular≠B-OSE_Labeled_AE   regenerative≠I-OSE_Labeled_AE   hyperplasia≠I-OSE_Labeled_AE                 0.4              ND                0                0          
  Portal≠B-OSE_Labeled_AE   hypertension≠I-OSE_Labeled_AE                              0.4              0.2               0                0          
    Immune≠B-NonOSE_AE   System≠I-NonOSE_AE   Disorders≠I-NonOSE_AE                   
  Drug≠B-OSE_Labeled_AE   hypersensitivity≠I-OSE_Labeled_AE                            2.2               0               0.8               0          
    Injury≠B-NonOSE_AE  ,≠I-NonOSE_AE   Poisoning≠I-NonOSE_AE  ,≠I-NonOSE_AE   and≠I-NonOSE_AE   Procedural≠I-NonOSE_AE         
  Infusion≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  related≠I-OSE_Labeled_AE   reaction≠I-OSE_Labeled_AE                        1.4               0               0.2               0          
    Infections≠B-NonOSE_AE   and≠I-NonOSE_AE   Infestations≠I-NonOSE_AE               
  Urinary≠B-OSE_Labeled_AE   tract≠I-OSE_Labeled_AE   infection≠I-OSE_Labeled_AE                          9.4              0.6              3.9               0          
    Investigations≠B-NonOSE_AE                            
  Blood≠B-OSE_Labeled_AE   alkaline≠I-OSE_Labeled_AE   phosphatase≠I-OSE_Labeled_AE   increased≠I-OSE_Labeled_AE             4.7              0.4              3.7              0.4         
  Increased≠B-OSE_Labeled_AE   transaminases≠I-OSE_Labeled_AE                         28.8              8.0             14.3              2.5         
    Metabolism≠B-NonOSE_AE   and≠I-NonOSE_AE   Nutrition≠I-NonOSE_AE   Disorders≠I-NonOSE_AE        
  Hypokalemia≠B-OSE_Labeled_AE                                     10.2              2.7              9.4              4.7         
    Musculoskeletal≠B-NonOSE_AE   and≠I-NonOSE_AE   Connective≠I-NonOSE_AE   Tissue≠I-NonOSE_AE   Disorders≠I-NonOSE_AE      
  Myalgia≠B-OSE_Labeled_AE                                         14.1              0.6              3.7               0          
  Arthralgia≠B-OSE_Labeled_AE                                      19.2              0.6              8.4               0          
  Musculoskeletal≠B-OSE_Labeled_AE   pain≠I-OSE_Labeled_AE                            36.1              1.8             30.5              1.4         
    Nervous≠B-NonOSE_AE   System≠I-NonOSE_AE   Disorders≠I-NonOSE_AE                  
  Dysgeusia≠B-OSE_Labeled_AE                                        8.0               0               4.1              0.2         
  Dizziness≠B-OSE_Labeled_AE                                       10.2              0.4             10.7              0.2         
  Peripheral≠B-OSE_Labeled_AE   neuropathy≠I-OSE_Labeled_AE                           21.2              2.2             13.5              0.2         
  Headache≠B-OSE_Labeled_AE                                        28.2              0.8             14.5              0.8         
    Psychiatric≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                     
  Insomnia≠B-OSE_Labeled_AE                                        12.0              0.4              8.6              0.2         
    Respiratory≠B-NonOSE_AE  ,≠I-NonOSE_AE   Thoracic≠I-NonOSE_AE  ,≠I-NonOSE_AE   and≠I-NonOSE_AE   Mediastinal≠I-NonOSE_AE   Disorders≠I-NonOSE_AE      
  Pneumonitis≠B-OSE_Labeled_AE                                      1.2               0                0                0          
  Dyspnea≠B-OSE_Labeled_AE                                         12.0              0.8              8.0              0.4         
  Cough≠B-OSE_Labeled_AE                                           18.2              0.2             13.1              0.2         
  Epistaxis≠B-OSE_Labeled_AE                                       22.5              0.2              8.4               0          
    Skin≠B-NonOSE_AE   and≠I-NonOSE_AE   Subcutaneous≠I-NonOSE_AE   Tissue≠I-NonOSE_AE   Disorders≠I-NonOSE_AE      
  Pruritus≠B-OSE_Labeled_AE                                         5.5              0.2              9.2               0          
  Rash≠B-OSE_Labeled_AE                                            11.6               0              27.5              1.8         
    Vascular≠B-NonOSE_AE   Disorders≠I-NonOSE_AE                        
  Hemorrhage≠B-OSE_Labeled_AE                                      32.2              1.8             16.4              0.8         
  Hypertension≠B-OSE_Labeled_AE                                     5.1              1.2              2.3              0.4         
          Table 7 Selected Laboratory Abnormalities 
 Parameter                     KADCYLA(3.6 mg/kg)  Lapatinib (1250 mg) + Capecitabine (2000 mg/m  2  )   
 All Grade %                    Grade 3 %     Grade 4 %    All Grade %    Grade 3 %     Grade 4 %     
  
  Increased≠B-OSE_Labeled_AE   bilirubin≠I-OSE_Labeled_AE                 17            <1            0             57            2             0         
  Increased≠B-OSE_Labeled_AE   AST≠I-OSE_Labeled_AE                       98            7             <1            65            3             0         
  Increased≠B-OSE_Labeled_AE   ALT≠I-OSE_Labeled_AE                       82            5             <1            54            3             0         
  Decreased≠B-OSE_Labeled_AE   platelet≠I-OSE_Labeled_AE   count≠I-OSE_Labeled_AE            83            14            3             21            <1            <1        
  Decreased≠B-OSE_Labeled_AE   hemoglobin≠I-OSE_Labeled_AE                60            4             1             64            3             <1        
  Decreased≠B-OSE_Labeled_AE   neutrophils≠I-OSE_Labeled_AE               39            3             <1            38            6             2         
  Decreased≠B-OSE_Labeled_AE   potassium≠I-OSE_Labeled_AE                 33            3             0             31            6             <1        
              Hepatic≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE  has been observed in two patients (0.2%) with  HER≠B-Not_AE_Candidate  2≠I-Not_AE_Candidate  -≠I-Not_AE_Candidate  positive≠I-Not_AE_Candidate  metastatic  breast≠I-Not_AE_Candidate   cancer≠I-Not_AE_Candidate  in clinical trials (n=884) with KADCYLA as single-agent.
 

   6.2 Immunogenicity

  As with all therapeutic proteins, there is the potential for an  immune≠B-OSE_Labeled_AE   response≠I-OSE_Labeled_AE   to≠I-OSE_Labeled_AE   KADCYLA≠I-OSE_Labeled_AE .



 A total of 836 patients from six clinical studies were tested at multiple time points for  anti≠B-NonOSE_AE  -≠I-NonOSE_AE  therapeutic≠I-NonOSE_AE   antibody≠I-NonOSE_AE   (≠I-NonOSE_AE  ATA≠I-NonOSE_AE ) responses to KADCYLA. Following KADCYLA dosing, 5.3% (44/836) of patients tested  positive≠B-OSE_Labeled_AE   for≠I-OSE_Labeled_AE   anti≠I-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  KADCYLA≠I-OSE_Labeled_AE   antibodies≠I-OSE_Labeled_AE  at one or more post-dose time points. The presence of KADCYLA in patient serum at the time of  ATA≠B-NonOSE_AE  sampling may interfere with the ability of this assay to detect  anti≠B-NonOSE_AE  -≠I-NonOSE_AE  KADCYLA≠I-NonOSE_AE   antibodies≠I-NonOSE_AE . As a result, data may not accurately reflect the true incidence of  anti≠B-NonOSE_AE  -≠I-NonOSE_AE  KADCYLA≠I-NonOSE_AE   antibody≠I-NonOSE_AE  development. In addition,  neutralizing≠B-NonOSE_AE   activity≠I-NonOSE_AE   of≠I-NonOSE_AE   anti≠I-NonOSE_AE  -≠I-NonOSE_AE  KADCYLA≠I-NonOSE_AE   antibodies≠I-NonOSE_AE  has not been assessed.



  Immunogenicity≠B-NonOSE_AE  data are highly dependent on the sensitivity and specificity of the test methods used. Additionally, the observed incidence of a positive result in a test method may be influenced by several factors, including sample handling, timing of sample collection, drug interference, concomitant medication and the underlying disease. Therefore, comparison of the incidence of  antibodies≠B-NonOSE_AE   to≠I-NonOSE_AE   KADCYLA≠I-NonOSE_AE  with the incidence of  antibodies≠B-NonOSE_AE   to≠I-NonOSE_AE   other≠I-NonOSE_AE   products≠I-NonOSE_AE  may be misleading. Clinical significance of  anti≠B-NonOSE_AE  -≠I-NonOSE_AE  KADCYLA≠I-NonOSE_AE   antibodies≠I-NonOSE_AE  is not yet known.
